Physician

Hamidreza Sanatinia, MD

According to 2025 Medicare claims, Hamidreza Sanatinia, MD (NPI: 1538178991) practices hematology/oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (NPI: 1598770471; TIN: 88-0350180) and primary practice location at 89148-4861.

Sanatinia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 747 traditional Medicare patients, billed 173,350 HCPCS/CPT codes, and received $2,619,660 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,064 prescription claims across 188 beneficiaries totaling $3,313,240 in drug costs, led by Ibrance (Palbociclib). DME data shows 39 claims. Open Payments data shows 165 records totaling $3,362. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,375,888 to $3,313,240. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	724	263,970	$2,091,838
2016	787	260,359	$2,595,057
2017	813	279,178	$3,519,767
2018	827	251,425	$3,479,777
2019	880	250,132	$3,089,392
2020	821	235,505	$3,273,534
2021	859	192,442	$2,626,368
2022	843	182,410	$2,708,688
2023	782	155,259	$2,371,331
2024	747	173,350	$2,619,660

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	153	881	$1,375,888
2016	151	906	$2,063,330
2017	206	1,363	$2,540,533
2018	213	1,419	$2,443,633
2019	199	1,194	$2,072,805
2020	214	1,328	$2,746,080
2021	202	1,062	$2,106,842
2022	188	891	$2,420,472
2023	175	889	$2,788,615
2024	188	1,064	$3,313,240

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	135	$11,696
2016	N/R	107	$22,086
2017	N/R	N/R	N/R
2018	N/R	58	$8,727
2019	N/R	130	$18,365
2020	N/R	171	$39,997
2021	N/R	115	$9,883
2022	N/R	136	$48,285
2023	N/R	72	$15,921
2024	N/R	39	$1,109

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	332	721	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	278	405	$68
80053	Blood test, comprehensive group of blood chemicals	321	811	$10
36415	Insertion of needle into vein for collection of blood sample	455	1,224	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	448	1,269	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	42	1,176	$722,998
Lenalidomide	Lenalidomide	36	994	$472,591
Revlimid	Lenalidomide	28	665	$323,104
Calquence	Acalabrutinib Maleate	19	570	$293,961
Venclexta	Venetoclax	23	676	$276,433

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$789
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$320

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	165	$3,362	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hamidreza Sanatinia, MD?

Tedicare shows public-source Medicare data for Hamidreza Sanatinia, MD (NPI 1538178991), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hamidreza Sanatinia, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hamidreza Sanatinia, MD?

Hamidreza Sanatinia, MD is linked to ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (billing NPI 1598770471) in the available physician profile data.

Does Hamidreza Sanatinia, MD have Open Payments data?

Hamidreza Sanatinia, MD has 165 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.